• Login
    ARAN - Access to Research at NUI Galway
    View Item 
    •   ARAN Home
    • Support Services
    • Externally hosted open access publications with NUI Galway authors (2)
    • View Item
    •   ARAN Home
    • Support Services
    • Externally hosted open access publications with NUI Galway authors (2)
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ARANCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsTypesThis CollectionBy Issue DateAuthorsTitlesSubjectsTypes

    My Account

    LoginRegister

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Help

    How to submit and FAQs

    Thyroid hormone treatment among pregnant women with subclinical hypothyroidism: us national assessment

    Thumbnail
    View/Open
    Full Text
    Date
    2017-01-25
    Author
    Maraka, Spyridoula
    Mwangi, Raphael
    McCoy, Rozalina G
    Yao, Xiaoxi
    Sangaralingham, Lindsey R
    Singh Ospina, Naykky M
    O’Keeffe, Derek T
    De Ycaza, Ana E Espinosa
    Rodriguez-Gutierrez, Rene
    Coddington, Charles C
    Stan, Marius N
    Brito, Juan P
    Montori, Victor M
    Metadata
    Show full item record
    Usage
    This item's downloads: 0 (view details)
    Cited 62 times in Scopus (view citations)
    
    Recommended Citation
    Maraka, Spyridoula; Mwangi, Raphael; McCoy, Rozalina G; Yao, Xiaoxi; Sangaralingham, Lindsey R; Singh Ospina, Naykky M; O’Keeffe, Derek T; De Ycaza, Ana E Espinosa; Rodriguez-Gutierrez, Rene; Coddington, Charles C; Stan, Marius N; Brito, Juan P; Montori, Victor M (2017). Thyroid hormone treatment among pregnant women with subclinical hypothyroidism: us national assessment. BMJ 356 ,
    Published Version
    http://www.bmj.com/content/bmj/356/bmj.i6865.full.pdf
    Abstract
    OBJECTIVE To estimate the effectiveness and safety of thyroid hormone treatment among pregnant women with subclinical hypothyroidism. DESIGN Retrospective cohort study. SETTING Large US administrative database between 1 January 2010 and 31 December 2014. PARTICIPANTS 5405 pregnant women with subclinical hypothyroidism, defined as untreated thyroid stimulating hormone (TSH) concentration 2.5-10 mIU/L. EXPOSURE Thyroid hormone therapy. MAIN OUTCOME MEASURE Pregnancy loss and other pre-specified maternal and fetal pregnancy related adverse outcomes. RESULTS Among 5405 pregnant women with subclinical hypothyroidism, 843 with a mean pre-treatment TSH concentration of 4.8 (SD 1.7) mIU/L were treated with thyroid hormone and 4562 with a mean baseline TSH concentration of 3.3 (SD 0.9) mIU/L were not treated (P< 0.01). Compared with the untreated group, treated women had lower adjusted odds of pregnancy loss (odds ratio 0.62, 95% confidence interval 0.48 to 0.82) but higher odds of preterm delivery (1.60, 1.14 to 2.24), gestational diabetes (1.37, 1.05 to 1.79), and pre-eclampsia (1.61, 1.10 to 2.37); other pregnancy related adverse outcomes were similar between the two groups. The adjusted odds of pregnancy loss were lower in treated women than in untreated women if their pre-treatment TSH concentration was 4.1-10 mIU/L (odds ratio 0.45, 0.30 to 0.65) but not if it was 2.5-4.0 mIU/L (0.91, 0.65 to 1.23) (P< 0.01). CONCLUSION Thyroid hormone treatment was associated with decreased risk of pregnancy loss among women with subclinical hypothyroidism, especially those with pre-treatment TSH concentrations of 4.1-10 mIU/L. However, the increased risk of other pregnancy related adverse outcomes calls for additional studies evaluating the safety of thyroid hormone treatment in this patient population.
    URI
    http://hdl.handle.net/10379/12637
    Collections
    • Externally hosted open access publications with NUI Galway authors (2)
    • Copyright @ NUI Galway
    • Library
    • NUI Galway